Table 1.

Area under the intracellular concentration versus time curve (AUC) after treatment with MK-4 or MKH-DMG in HCC cell lines

HCC cell lineTest drugAUC0–72 h for MKO (nmol.h/mg protein)AUC0–72 h for MK-4 (nmol.h/mg protein)AUC0–72 h for MKHa (nmol.h/mg protein)
PLC/PRF/5MK-422.2 ± 3.7247.7 ± 7.2522.2 ± 3.72
MKH-DMG193 ± 25.1143 ± 13.6336 ± 37.2
Hep3BMK-4113 ± 4.8774.5 ± 17.0113 ± 4.87
MKH-DMG371 ± 31.025.9 ± 5.04397 ± 34.2
SK-Hep-1MK-438.4 ± 4.44122 ± 19.538.4 ± 4.44
MKH-DMG136 ± 14.3193 ± 21.5329 ± 35.4

NOTE: Doses are 25 μmol/L (at near IC50 value). PLC/PRF/5 and Hep3B, DCP-positive cells; SK-Hep-1, DCP-negative cells.

  • aMKH value after MKH-DMG administration: sum of MKO and MK-4. MKH value after MK-4 administration: MKO.